Authors

Latest:

Informed Patients Are More Likely to Choose Palliative Care

Research from Tulane University provides a strong case that, across demographic and clinical populations, informed patients are less wary of palliative care and more inclined to take advantage of the favorable effects that palliative care services can offer for patient-centered outcomes.

Michael I. D'Angelica, MD, FACS

Latest:

Hepatic Infusion Can Convert CRC Liver Metastases to Operable State

Overall, compelling response rates and rates of conversion to resection for patients with initially unresectable colorectal liver metastases treated with hepatic arterial infusion suggest consideration of earlier initiation of the technique in chemotherapy-naïve patients as well as its adoption in patients who have failed first-line systemic chemotherapy before proceeding to second- or third-line regimens.

Michael J. Birrer, MD, PhD, University of Arkansas Medical Center

Latest:

Practical Implications for Treatment Strategies in Advanced Ovarian Cancer

Michael J. Birrer, MD, PhD, Mass Gen

Michael J. Birrer, MD, PhD, Mass General

Michael J. Birrer, MD, PhD, O'Neal Comprehensive Cancer Center

Michael J. Birrer, MD, PhD, The University of Alabama at Birmingham

Michael J. Guarino, MD

Latest:

Dr. Guarino on IMMU-132 in Advanced Metastatic Lung Cancer

Michael J. Guarino, MD, senior staff member, Christiana Care's Department of Medicine, partner, Medical Oncology Hematology Consultants, Christiana Care's Helen F. Graham Cancer Center, discusses initial data from a phase I/ll study examining an anti-Î¤ROP-2-SN-38 antibody-drug conjugate, sacituzumab govitecan (IMMU-132), as therapy for advanced metastatic lung cancer.

Michael J. Hall, MD

Latest:

Dr. Hall on Multigene Target Panels for Genetic Weaknesses

Michael J. Hall, MD, MS, director, Gastrointestinal Risk Assessment, assistant professor, Fox Chase Cancer Center, discusses multigene target panels that examine tumors for genetic weaknesses.

Michael J. Hall, MD, MS

Latest:

Dr. Hall on the Importance of Genetic Testing in Pancreatic Cancer

Michael J. Hall, MD, MS, chair, Department of Clinical Genetics, director, Gastrointestinal Risk Assessment, associate professor, Fox Chase Cancer Center, discusses the importance of genetic testing in pancreatic cancer.

Michael J. Keating, MD, BS

Latest:

Rituximab for Chronic Lymphocytic Leukemia in Treatment-Naïve and Treatment-Experienced Patients

A mixed treatment comparison demonstrated that FCR significantly prolonged PFS compared with all other treatments and significantly increased ORR compared with all other treatments.

Michael J. Mauro, MD

Michael J. Mauro, MD, is attending physician at Memorial Sloan Kettering Cancer Center

Latest:

Dr Mauro on How Genetic Alterations Impact TKI Decisions in CML

Michael J. Mauro, MD, discusses how genetic alterations, such as BCR::ABL mutations, inform treatment decisions in CML.

Michael J. Mauro, MD Memorial Sloan Kettering Cancer Center

Michael J. Morris, MD

Michael J. Morris, MD, is a medical oncologist and section head of Prostate Cancer, GU Oncology, at Memorial Sloan Kettering Cancer Center

Latest:

Dr Morris on the FDA's Expanded Approval of Lutetium Lu 177 Vipivotide Tetraxetan for PSMA+ mCRPC

Michael J. Morris, MD, discusses the FD expanded approval of lutetium Lu 177 vipivotide tetraxetan for the treatment of patients with PSMA-positive mCRPC.

Michael J. Overman, MD

Latest:

Dr Overman on Future Research Directions in GI Cancer

Michael J. Overman, MD, discusses future research directions in gastrointestinal cancers.

Mike J. Pishvaian, MD, PhD

Mike J. Pishvaian, MD, PhD, is director of Gastrointestinal, Developmental Therapeutics and Clinical Research Programs and an associate professor of oncology at Johns Hopkins Medicine in Baltimore, Maryland.

Latest:

How the Mechanisms of KRAS(ON) Inhibitors Differ From KRAS(OFF) Inhibitors

Mike J. Pishvaian, MD, PhD, and Martin Dietrich, MD, PhD, discuss how KRAS(ON) inhibitors differ in mechanism from KRAS(OFF) inhibitors.

Michael J. Thirman, MD

Latest:

Closing Perspectives on R/R AML Treatment Advances

Panelists discuss future perspectives on the role of menin inhibitors in the treatment of acute lymphoblastic leukemia (AML), exploring potential advancements and clinical implications.

Michael K. Brawer, MD

Latest:

Dr. Michael Brawer on Predicting Prostate Cancer Aggressiveness

Michael K. Gould, MD, MS

Latest:

Dr. Gould on the Implications of the NELSON Trial in Lung Cancer

Michael K. Gould, MD, MS, pulmonologist and director of the Division of Health Services Research and Implementation Science at Kaiser Permanente Southern California, discusses the implications of the NELSON trial in lung cancer.

Michael K. Keng, MD

Latest:

It's Time to Take Action on Quality Measures

Quality improvement is a method for ensuring that all the activities necessary to design, develop, and implement a product or service are effective and efficient with respect to the system and its performance.